| Systematic (IUPAC) name | |
|---|---|
| (RS)-5-[(2- cyclopropyl- 7,8-dimethoxy- 2H- chromen- 5-yl) methyl] pyrimidine- 2,4- diamine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Routes | Intravenous (oral under investigation) |
| Pharmacokinetic data | |
| Bioavailability | Good (oral)[1] |
| Identifiers | |
| CAS number | 192314-93-5 |
| ATC code | J01EA03 |
| PubChem | CID 213043 |
| UNII | 42445HUU0O |
| KEGG | D08337 |
| ChEMBL | CHEMBL134561 |
| Chemical data | |
| Formula | C19H22N4O3 |
| Mol. mass | 354.403 g/mol |
| SMILES | eMolecules & PubChem |
| (what is this?) (verify) |
|
Iclaprim (INN), codenamed AR-100 and RO-48-2622, is a diaminopyrimidine dihydrofolate reductase inhibitor being developed for the treatment of complicated skin and soft tissue infections caused by antibiotic-resistant bacteria. It is structurally related to trimethoprim. In Phase III clinical trials, intravenously-administered iclaprim was found to be as effective as and better tolerated than linezolid in people with skin and soft tissue infections, many caused by methicillin-resistant Staphylococcus aureus (MRSA).[2][3] In vitro, iclaprim is highly active against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria.[1]
A new drug application for iclaprim was filed with the U.S. Food and Drug Administration in March 2008,[2] and a marketing authorisation application (MAA) was accepted by the European Medicines Agency on August 21, 2008. Phase II clinical trials are being conducted to assess whether iclaprim can be taken by mouth as well as intravenously and whether it is effective for the treatment of hospital-acquired pneumonia.[3][4]
Iclaprim has been granted fast track status by the FDA.[5]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||